English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The use of autologous skin grafts comprises a well established method of reconstruction in large areas involving partial thickness defects. Additionally, when skin availability is limited due to associated trauma or injury (e.g. burns) the use of homologous skin grafts from a compatible donor appears to be a valid alternative. The effort to maximize effectiveness of skin grafting in terms of increasing graft take, protecting viability, reducing full healing time and achieving improved postoperative outcomes without impairing function has also been constant especially in cases of impaired general condition. Human recombinant erythropoietin (rHuEPO) is a glycoprotein with primarily a hemopoietic role due to the inhibition of precursor erythrocytes and the promotion of their proliferation. Its genetic expression is being regulated by hypoxia. It is primarily synthesized by the fetal kidneys and liver and by the adult kidneys (Paschos et al. 2008). The biological activity of rHuEPO is promoted by its interaction with the cell surface erythropoietin receptor (EPOR) (Brines and Ceramic 2008) which is a type I cytokine expressed by precursor erythrocytes as well as in other non hemopoietic systems such as the central and the peripheral nervous system in response to trauma (Galeano et al. 2004), in cardiac muscle cells, vascular endothelial smooth muscle cells and in subcutaneous mast cells with potent anti-ischaemic action (Brines and Ceramic, 2008; Galeano et al. , 2004). Current research has focused on its non-hemopoietic role. Many studies report the local production of erythropoietin (EPO) in response to trauma prior to the local concentration of pre-inflammatory cytokines and EPO acting antagonistically to them by reducing edema, inhibiting cellular apoptosis, promoting neovascularization by enhancing endothelial cell mitosis and promoting wound healing (Paschos et al. 2008). Since endogenous local EPO production is inadequate, it has been shown that the exogenous administration of rHuEPO enhanced wound healing and revascularization in experimental

intech ebooks

The Effect of Human Recombinant Erythropoietin (rHuEPO) and Tacrolimus (FK506) in Autologous and Homologous Full Thickness Skin Graft (FTSG) Take and Viability in a Rat Model